IDH1 and central nervous system cancer: In 125 gliomas, we detected the IDH1/2 mutation in 58 cases, co-deletion of chromosome arms 1p and 19q (1p/19q co-deletion) in 22 cases (22/125, 17.6%), IDH1/2 mutation and 1p/19q codeletion in 16 cases, wildtype IDH1/2 with 1p/19q- co-deletion in six patients, and the pTERT mutation in 64 cases (64/125; 51.2%), with C228T and C250T mutation rates of 76.56 (49/64) and 23.44% (15/64), respectively.